| Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 |
1199 |
| Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017 |
763 |
| Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 |
735 |
| Food in the Anthropocene: the EAT-Lancet Commission on healthy diets from sustainable food systems |
718 |
| Hepatocellular carcinoma |
648 |
| Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 |
614 |
| Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial |
545 |
| Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries |
475 |
| Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial |
456 |
| Health effects of dietary risks in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 |
435 |
| SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials |
420 |
| Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 |
413 |
| The Lancet Commission on pollution and health |
404 |
| Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial |
341 |
| Estimates of global seasonal influenza-associated respiratory mortality: a modelling study |
320 |
| Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis |
302 |
| Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase open-label trial |
292 |
| International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study |
291 |
| What low back pain is and why we need to pay attention |
291 |
| Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 |
261 |
| Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial |
257 |
| The Global Syndemic of Obesity, Undernutrition, and Climate Change: The Lancet Commission report |
254 |
| Osteoarthritis |
244 |
| Asthma |
226 |
| Multiple sclerosis |
223 |
| Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial |
219 |
| Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories |
218 |
| Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial |
215 |
| Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study |
211 |
| Colorectal cancer |
209 |
| Leishmaniasis |
207 |
| The Lancet Commission on global mental health and sustainable development |
202 |
| Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study |
201 |
| Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial |
201 |
| Prevention and treatment of low back pain: evidence, challenges, and promising directions |
198 |
| Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study |
196 |
| Depression |
193 |
| Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial |
192 |
| Oral diseases: a global public health challenge |
189 |
| Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase randomised controlled trial |
185 |
| The 2019 report of The Lancet Countdown on health and climate change: ensuring that the health of a child born today is not defined by a changing climate |
182 |
| Nasopharyngeal carcinoma |
181 |
| Osteoporosis |
174 |
| Cervical cancer |
171 |
| Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial |
170 |
| Melanoma |
167 |
| Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial |
162 |
| Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies |
161 |
| Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial |
159 |
| Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017 |
154 |
| Chagas disease |
152 |
| Global epidemiology of use of and disparities in caesarean sections |
151 |
| Sarcopenia |
149 |
| Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study |
148 |
| Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial |
141 |
| The Lancet Countdown on health and climate change: from 25 years of inaction to a global transformation for public health |
139 |
| Epithelial ovarian cancer |
138 |
| Sepsis and septic shock |
138 |
| Carbohydrate quality and human health: a series of systematic reviews and meta-analyses |
137 |
| After asthma: redefining airways diseases |
136 |
| Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial |
135 |
| Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial |
132 |
| Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study |
131 |
| Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016 |
128 |
| Primary brain tumours in adults |
125 |
| Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study |
125 |
| Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial |
123 |
| Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial |
123 |
| Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial |
122 |
| Short-term and long-term effects of caesarean section on the health of women and children |
121 |
| Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial |
119 |
| Before the beginning: nutrition and lifestyle in the preconception period and its importance for future health |
117 |
| Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial |
116 |
| Coeliac disease |
116 |
| Autism spectrum disorder |
116 |
| Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials |
115 |
| Origins of lifetime health around the time of conception: causes and consequences |
115 |
| Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis |
114 |
| Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial |
114 |
| Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials |
113 |
| Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial |
111 |
| Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial |
111 |
| The 2018 report of the Lancet Countdown on health and climate change: shaping the health of nations for centuries to come |
110 |
| Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study |
108 |
| Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis |
106 |
| Alleviating the access abyss in palliative care and pain relief-an imperative of universal health coverage: the Lancet Commission report |
105 |
| Frailty: implications for clinical practice and public health |
103 |
| Age-related macular degeneration |
103 |
| Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study |
100 |
| Global alcohol exposure between 1990 and 2017 and forecasts until 2030: a modelling study |
100 |
| Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals |
99 |
| Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial |
99 |
| Deep learning algorithms for detection of critical findings in head CT scans: a retrospective study |
95 |
| NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4 |
95 |
| Efficacy and safety of LY329 a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial |
94 |
| Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase non-inferiority trial |
94 |
| Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial |
94 |
| Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial |
94 |
| Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial |
93 |
| Development and validation of a Hospital Frailty Risk Score focusing on older people in acute care settings using electronic hospital records: an observational study |
93 |
| Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials |
92 |
| Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis |
90 |
| An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: a retrospective analysis of outcome prediction |
90 |
| Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data |
89 |
| Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial |
87 |
| Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial |
86 |
| Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial |
86 |
| Acute kidney injury |
85 |
| Epilepsy in adults |
84 |
| Ending the neglect of global oral health: time for radical action |
84 |
| Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study |
84 |
| Accelerate progress-sexual and reproductive health and rights for all: report of the Guttmacher-Lancet Commission |
84 |
| Thalassaemia |
83 |
| Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis |
83 |
| Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial |
83 |
| Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial |
80 |
| The UCL-Lancet Commission on Migration and Health: the health of a world on the move |
80 |
| Type 1 diabetes |
80 |
| Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial |
80 |
| Prenatal exome sequencing analysis in fetal structural anomalies detected by ultrasonography (PAGE): a cohort study |
79 |
| Police killings and their spillover effects on the mental health of black Americans: a population-based, quasi-experimental study |
77 |
| Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial |
77 |
| Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017 |
76 |
| Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety |
76 |
| Acute myeloid leukaemia |
75 |
| Population and fertility by age and sex for 195 countries and territories, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017 |
75 |
| Morbidity and mortality in homeless individuals, prisoners, sex workers, and individuals with substance use disorders in high-income countries: a systematic review and meta-analysis |
74 |
| Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study |
74 |
| Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial |
72 |
| Dengue |
72 |
| Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial |
72 |
| Soil-transmitted helminth infections |
71 |
| Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial |
71 |
| Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial |
70 |
| Hip arthroscopy versus best conservative care for the treatment of femoroacetabular impingement syndrome (UK FASHIoN): a multicentre randomised controlled trial |
70 |
| Neurodevelopmental outcome at 5 years of age after general anaesthesia or awake-regional anaesthesia in infancy (GAS): an international, multicentre, randomised, controlled equivalence trial |
70 |
| Gender inequality and restrictive gender norms: framing the challenges to health |
69 |
| Brazil's unified health system: the first 30 years and prospects for the future |
68 |
| Malaria |
68 |
| Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome |
68 |
| Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial |
68 |
| Management of frailty: opportunities, challenges, and future directions |
67 |
| Endoscopic or surgical step-up approach for infected necrotising pancreatitis: a multicentre randomised trial |
67 |
| Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials |
67 |
| Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial |
67 |
| New WHO prevalence estimates of mental disorders in conflict settings: a systematic review and meta-analysis |
66 |
| Individualised nutritional support in medical inpatients at nutritional risk: a randomised clinical trial |
65 |
| Hip and knee replacement 2 Knee replacement |
65 |
| 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial |
65 |
| Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials |
64 |
| Tuberculosis |
64 |
| Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase randomised, controlled study |
64 |
| Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial |
64 |
| Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial |
64 |
| Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials |
64 |
| Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence |
64 |
| Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial |
64 |
| Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study |
64 |
| Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological diseasemodifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial |
63 |
| Frozen versus fresh single blastocyst transfer in ovulatory women: a multicentre, randomised controlled trial |
63 |
| Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial |
63 |
| Extending thrombolysis to 4.5-9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data |
63 |
| NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial |
63 |
| Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data |
63 |
| Interventions to reduce unnecessary caesarean sections in healthy women and babies |
63 |
| Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial |
63 |
| Principles of DNA methylation and their implications for biology and medicine |
62 |
| 10 years of health-care reform in China: progress and gaps in Universal Health Coverage |
62 |
| Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial |
62 |
| Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial |
61 |
| Enteral versus parenteral early nutrition in ventilated adults with shock: a randomised, controlled, multicentre, open-label, parallel-group study (NUTRIREA-2) |
61 |
| Perioperative patient outcomes in the African Surgical Outcomes Study: a 7-day prospective observational cohort study |
59 |
| Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial |
58 |
| Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial |
58 |
| Past, present, and future of global health financing: a review of development assistance, government, out-of-pocket, and other private spending on health for 195 countries, 1995-2050 |
58 |
| Chronic hepatitis B virus infection |
57 |
| Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial |
57 |
| Whole-exome sequencing in the evaluation of fetal structural anomalies: a prospective cohort study |
57 |
| Burden of disease in Brazil, 1990-2016: a systematic subnational analysis for the Global Burden of Disease Study 2016 |
56 |
| Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial |
55 |
| Building a tuberculosis-free world: The Lancet Commission on tuberculosis |
55 |
| Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase randomised, non-inferiority SWORD-1 and SWORD-2 studies |
55 |
| Migraine |
54 |
| Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial |
54 |
| Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial |
54 |
| Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study |
54 |
| Hyperparathyroidism |
54 |
| How long does a hip replacement last? A systematic review and meta-analysis of case series and national registry reports with more than 15 years of follow-up |
53 |
| Aspiration thrombectomy versus stent retriever thrombectomy as first-line approach for large vessel occlusion (COMPASS): a multicentre, randomised, open label, blinded outcome, non-inferiority trial |
53 |
| Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial |
53 |
| Intervention strategies to improve nutrition and health behaviours before conception |
52 |
| Urinary sodium excretion, blood pressure, cardiovascular disease, and mortality: a community-level prospective epidemiological cohort study |
52 |
| Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study |
52 |
| Intracerebral haemorrhage: current approaches to acute management |
52 |
| Management of opioid use disorder in the USA: present status and future directions |
52 |
| Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial |
52 |
| The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications |
51 |
| Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial |
51 |
| The state of hypertension care in 44 low-income and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1.1 million adults |
51 |
| Efficacy and safety of one anastomosis gastric bypass versus Roux-en-Y gastric bypass for obesity (YOMEGA): a multicentre, randomised, open-label, non-inferiority trial |
51 |
